-+ 0.00%
-+ 0.00%
-+ 0.00%

FDA approves Pfizer's Tukysa regimen for front-line maintenance in HER2+ metastatic breast cancer

PUBT·10/07/2026 16:57:39
Listen to the news
FDA approves Pfizer's Tukysa regimen for front-line maintenance in HER2+ metastatic breast cancer
  • FDA cleared Pfizer’s Tukysa with trastuzumab, pertuzumab as front-line maintenance for unresectable locally advanced or metastatic HER2+ breast cancer.
  • HER2CLIMB-05 showed median PFS of 24.9 months vs 16.3 months for placebo, hazard ratio 0.64.
  • Label highlights higher hepatotoxicity risk; one fatal drug-induced liver injury reported in the trial.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261007040182) on October 07, 2026, and is solely responsible for the information contained therein.